These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20660846)

  • 41. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
    Spratt DE; Dai DLY; Den RB; Troncoso P; Yousefi K; Ross AE; Schaeffer EM; Haddad Z; Davicioni E; Mehra R; Morgan TM; Rayford W; Abdollah F; Trabulsi E; Achim M; Tapia ELN; Guerrero M; Karnes RJ; Dicker AP; Hurwitz MA; Nguyen PL; Feng FFY; Freedland SJ; Davis JW
    Eur Urol; 2018 Jul; 74(1):107-114. PubMed ID: 29233664
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
    Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
    J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Five-year downstream outcomes following prostate-specific antigen screening in older men.
    Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
    JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prostate cancer detection by prostate biopsy among Japanese with prostate-specific antigen below 4.0 ng/ml].
    Kanno T; Shibasaki N; Tsuji Y; Taki Y; Takeuchi H
    Hinyokika Kiyo; 2006 Mar; 52(3):181-4. PubMed ID: 16617870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
    Smitt MC; Heltzel M
    Cancer; 1996 Mar; 77(5):928-33. PubMed ID: 8608486
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histopathological findings in extended prostate biopsy with PSA < or = 4 ng/mL.
    Leite KR; Srougi M; Dall'Oglio MF; Sanudo A; Camara-Lopes LH
    Int Braz J Urol; 2008; 34(3):283-90; discussion 290-2. PubMed ID: 18601758
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.
    D'amico AV; Tempany CM; Schultz D; Cormack RA; Hurwitz M; Beard C; Albert M; Kooy H; Jolesz F; Richie JP
    Urology; 2003 Dec; 62(6):1063-7. PubMed ID: 14665356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
    Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
    BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
    Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
    Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
    Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
    Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Individualized estimates of overdiagnosis in screen-detected prostate cancer.
    Gulati R; Inoue LY; Gore JL; Katcher J; Etzioni R
    J Natl Cancer Inst; 2014 Feb; 106(2):djt367. PubMed ID: 24399850
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate cancer screening in the Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S; Zhu X; Schroder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
    Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
    J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
    Zheng Z; Zhou Z; Yan W; Zhou Y; Chen C; Li H; Ji Z
    BMC Cancer; 2020 Apr; 20(1):340. PubMed ID: 32321456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate Specific Antigen Nadir After Radical Cystoprostatectomy in Patients With Benign Prostatic Tissue: A Benchmark To Define Biochemical Recurrence after Radical Prostatectomy.
    Hosseini SY; Alemi M; Amini E; Riazi N
    Urol J; 2019 Dec; 16(6):563-566. PubMed ID: 31004342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.